Skinvisible Q2 FY26 net loss narrows to USD 255,533; revenue flat at USD 5,000
SKVI•Quarterly results narrow loss
- Skinvisible posted a net loss of USD 255,533 for Q2 2026, narrowing from a loss of USD 274,427 a year earlier.
- Revenue held flat at USD 5,000 versus the prior-year quarter, while operating expenses fell to USD 117,817 from USD 141,237.
- Interest expense drove other expenses of USD 142,716, little changed from USD 142,720 in the year-ago quarter.
Balance sheet and pipeline update
- Working capital deficit widened to USD 5.5 million at June 30, 2026, from USD 4.99 million at Dec. 31, 2025.
- Quoin’s QRX003 remains on track for Phase 3 recruitment completion by end-2026, with a potential FDA filing targeted for 2027.
